EP3386944A2 - Verfahren zur herstellung von lisdexamphetamin - Google Patents

Verfahren zur herstellung von lisdexamphetamin

Info

Publication number
EP3386944A2
EP3386944A2 EP16872573.7A EP16872573A EP3386944A2 EP 3386944 A2 EP3386944 A2 EP 3386944A2 EP 16872573 A EP16872573 A EP 16872573A EP 3386944 A2 EP3386944 A2 EP 3386944A2
Authority
EP
European Patent Office
Prior art keywords
formula
compound
reaction
lisdexamphetamine
amino protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16872573.7A
Other languages
English (en)
French (fr)
Other versions
EP3386944A4 (de
Inventor
Rajamannar Thennati
Srinivasu Kilaru
Sujit Sridhar PAWAR
Nileshkumar Sureshbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of EP3386944A2 publication Critical patent/EP3386944A2/de
Publication of EP3386944A4 publication Critical patent/EP3386944A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/16—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
    • C07D203/18—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof

Definitions

  • the present invention relates to a process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts via a novel aziridine intermediate.
  • Formula I is a conjugate of D-amphetamine and L-lysine and is chemically named as (25)-2,6-diamino-N- [(25)-methyl-2-phenylethyl]hexanamide. It is used for treatment of attention deficit hyperactivity disorder (ADHD).
  • ADHD attention deficit hyperactivity disorder
  • Lisdexamphetamine and its pharmaceutically acceptable salts were first disclosed in US patent 7662787 wherein it is exemplified as hydrochloride salt.
  • Process for preparation of lisdexamphetamine as disclosed comprises reaction of Boc-Lys-(Boc)-hydroxysuccinimido ester with D-amphetamine in 1,4-dioxane using NN-diisopropylethylamine (DIPEA) as a base to obtain Boc -protected lisdexamphetamine which is then purified using flash chromatography and further reacted with a mixture of 4M hydrochloric acid/dioxane to yield L-lysine-D- amphetamine hydrochloride.
  • DIPEA NN-diisopropylethylamine
  • the process includes preparation of Boc-Lys-(Boc)-hydroxysuccinimido ester wherein use of reagents like N-hydroxy-succinimide (NHS) and NN-dicyclohexyl-carbodimiide(DCC) is carried out.
  • reagents like N-hydroxy-succinimide (NHS) and NN-dicyclohexyl-carbodimiide(DCC) is carried out.
  • N-hydroxy-succinimide (NHS) and NN-dicyclohexyl-carbodimiide(DCC) is carried out.
  • the above processes involve use of flash column chromatography to purify crude Boc-protected L-lysine-D-amphetamine intermediate. Use of column chromatography is very cumbersome, tedious and time consuming, therefore not advisable at commercial scale.
  • alkylphosphonic acid anhydrides which are expensive and need additional testing to show absence of phosphoric impurities in intermediate or final compound to meet regulatory requirements. So it is not appealing to use alkylphosphonic anhydrides for scale up operations.
  • the present invention provides a process for preparation of lisdexamphetamine, a compound of Formula I or pharmaceutically acceptable salts thereof;
  • X and Y in compound of Formula ⁇ are independently selected from amino protecting groups or hydrogen; b) when X and/or Y in compound of Formula ⁇ are amino protecting group, deprotecting the compound of Formula ⁇ to obtain the compound of Formula I.
  • the present invention provides a process for preparation of lisdexamphetamine which involves the use of intermediates which are easily available, less expensive and easy to handle.
  • the present invention provides a process for preparation of lisdexamphetamine or pharmaceutically acceptable salts thereof.
  • X and Y in compound of Formula ⁇ are independently selected from amino protecting groups or hydrogen;
  • Protecting group, X and Y are defined as any group which is suitable to protect amino group for example i-butyloxycarbonyl (Boc), benzyloxycarbonyl (CBz), trifluoroacetyl (TBA), trimethylsilylethyloxycarbonyl (Teoc), allyloxycarbonyl (Alloc), fluorenylmethyloxycarbonyl (Fmoc) etc.
  • the preferred amino protecting groups are i-butyloxycarbonyl (Boc) or CBz.
  • step a the compound of Formula IV is subjected to reduction to form compound of Formula ⁇ .
  • the compound of Formula ⁇ represents a protected compound of Formula I wherein the two amino groups in the compound of Formula I are protected by amino protecting groups X and Y.
  • X and Y are hydrogen
  • the compound of Formula ⁇ is same as the compound of Formula I.
  • Reduction can be performed by hydrogenating a solution of compound of Formula IV in a suitable solvent in presence of a catalyst.
  • Catalyst can be selected from transition metal catalyst (usually Pd, Pt, Ni, or Rh).
  • the hydrogenating catalyst used is Pd/C.
  • Reaction can carried out in presence of a solvent selected from methanol, ethanol, n-propyl alcohol, isopropyl alcohol, tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile etc.
  • a solvent selected from methanol, ethanol, n-propyl alcohol, isopropyl alcohol, tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile etc.
  • the solvent used is isopropyl alcohol.
  • the reaction can be performed at room temperature for 7-8 hours. The completion of reaction can be monitored by thin layer chromatography (TLC).
  • TLC thin layer chromatography
  • the compound of Formula ⁇ can be isolated by any standard method known in the art typically the product is isolated by filtering off the catalyst and concentrating the filtrate.
  • step a When X or Y or both are protecting group, the product obtained in step a is subjected to deprotection to afford a compound of Formula I.
  • Deprotection can be carried by any method known in the prior art for example by using a suitable acid in presence of solvent or by hydrogenation depending upon the nature of the protecting group.
  • Suitable acid can be selected from the group consisting of methanesulphonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, orthophosphoric acid etc.
  • acid used is methanesulfonic acid.
  • Solvent can be selected from the group consisting aromatic hydrocarbon such as toluene, xylene, cyclohexane; ethers like tetrahydrofuran, 2-methyltetrahydrofuran and 1,4-dioxane etc.
  • the solvent used is 1 ,4-dioxane.
  • the reaction can be performed at temperature below 25 °C for 4-5 hours. The completion of reaction can be monitored by thin layer chromatography (TLC).
  • TLC thin layer chromatography
  • the product can be isolated by any method known in the art; typically the product is isolated by filtration. Lisdexamphetamine obtained by step a or step b can optionally be converted to its pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salt may be obtained by any of the methods known in the prior art, for instance, by treating it with a suitable acid in presence of solvent.
  • Solvent can be selected from the group consisting hydrocarbon such as toluene, xylene, cyclohexane; ethers like tetrahydrofuran, 2-methyltetrahydrofuran and 1 ,4-dioxane etc.
  • the solvent used is 1,4-dioxane.
  • TLC thin layer chromatography
  • the product can be isolated by any standard method known in the art, typically the product is isolated by filtration.
  • the compounds of Formula IV have favorable physical properties which facilitate ease of handling, storage, transportation etc.
  • a compound of Formula IV where X and Y are Boc is a crystalline free flowing solid hence, is easy to handle, store and transport.
  • the compound of Formula IV may be prepared by a process comprising coupling a compound of Formula II
  • the compound of Formula III (2S,3i?)-2-methyl-3-phenylaziridine, can be prepared as described in "Synthesis of 15 V-labeled vicinal diamines through N-activated chiral aziridines: Tools for the NMR study of platinum-based anticancer compounds, Tetrahedron Letters, 2013, Volume 54, Pages 545-548.”
  • Z is a leaving group formed by reacting the corresponding free carboxylic acid of the compound of Formula II with either a suitable acid activating agents like carbonyldiimidazole (CD I), l-(3- dimethylaminopropyl)-3-ethylcarbodiimide (EDCI), benzotriazol-1- yloxyin t v(pyrrolidino)phosphonium hexafluorophosphate (PyBOP), O-( lH-benzotriazol-l-yl)- N,N,N,N-tetramethyluronium hexafluorophosphate (HBTU) , N-hydroxybenzotriazole, N,N- dicyclohexyl-carbodimiide (DCC), N-hydroxysuccinimide (HOSu); or by reacting with a suitable halogenating agent.
  • the leaving group is chloro, bromo, iodo or hydroxysuccinimido ester (CD
  • the most preferred leaving group is hydroxysuccinimido ester (OSu).
  • Coupling of the compound of Formula II with the compound of Formula III can be conveniently carried out in presence of a solvent and a base.
  • Solvent can be selected from the group consisting of aromatic hydrocarbon such as toluene, xylene, cyclohexane; ethers like tetrahydrofuran, 2- methyltetrahydrofuran and 1,4-dioxane etc.
  • the solvent used is 1,4-dioxane.
  • a suitable base for the purpose can be selected from N-methylmorpholine, diisopropylethyl amine (DIPEA), triethylamine, tri-n-propylamine, tri-n-butylamine, pyridine and alkaline metal hydroxide & carbonates.
  • the base used is N-methylmorpholine.
  • the reaction can be performed at temperature range of 20-35 °C for 1-2 hours. The completion of reaction can be monitored by thin layer chromatography (TLC).
  • reaction product can be isolated as per any process under the purview of a person skilled in the art for example reaction mass is concentrated under vacuum and the residue obtained is dissolved in isopropyl acetate followed by washing with acid, a base followed by water, and concentrating the organic layer.
  • the product of the coupling step having X or Y or both as protecting groups can optionally be subjected for deprotection by method described earlier in the specification.
  • the present invention provides a compound of Formula IV
  • X and Y are independently selected from amino protecting groups or hydrogen.
  • Protecting group, X and Y are defined as any group which is suitable to protect amino group as described earlier in the specification.
  • the preferred amino protecting groups are t- butyloxycarbonyl (Boc) or CBz.
  • Boc-L-Lys(Boc)-OSu (compound of Formula II wherein X and Y both are, Boc & Z is OSu; 4.0 g) was dissolved in 1,4-dioxane (24.0 mL) under inert atmosphere and was stirred for 10-15 min. N-methylmorpholine (1.08 mL) was added to the mixture and was stirred for 10 min. A solution of (25,3i?)-2-methyl-3-phenylaziridine (compound of Formula III, 1.80 g) in 1 ,4-dioxane (8 mL) was slowly added maintaining temperature below 25 °C during addition. Resulting reaction mixture was stirred for an hour.
  • Diboc-Lysdex-aziridine (compound of Formula IV where X and Y both are, Boc; 3.0 g) was dissolved in isopropyl alcohol (IPA) (20.0 mL) and resulting solution was stirred for 15 minutes to obtain clear solution.
  • Pd/C (0.15 g) was added to the reaction mixture and was kept under hydrogen pressure for 5-6 hours at 40 psi. Then Pd/C was filtered and again fresh Pd/C (0.1 g) was added to the reaction mixture and was kept under 40 psi hydrogen pressure for 2 hour. Completion of reaction was checked by TLC. Pd/C was filtered and washed with IPA (6.0
  • the reaction mixture was then concentrated under reduced pressure below 80 °C.
  • Diboc-lisdexamphetamine (1.5 g) was dissolved in 1,4-dioxane (12.75 mL) and was kept under stirring for 15 min under inert atmosphere. Methanesulfonic acid (1.554 g) was slowly added to the reaction mixture with maintaining temperature below 25 °C. Reaction mixture was maintained under stirring for 4-5 hours. Completion of reaction was checked by TLC. Reaction mass was filtered and washed with dioxane (3.0 mL) to obtain white solid. End solid product was dried under vacuum overnight at 55- 60 °C.
  • Boc-L-Lys(Boc)-OSu (compound of Formula II where X and Y both are Boc & Z is OSu; 25.0 g) was dissolved in 1 ,4-dioxane (150.0 mL) under inert atmosphere and was stirred for 10-15 min. N-methylmorpholine (6.75 mL) was added to the mixture and was stirred for 10 min. A solution of (2S,3i?)-2-methyl-3-phenylaziridine (compound of Formula III, 11.30 g) in 1,4- dioxane (50 mL) was slowly added maintaining temperature below 25 °C during addition. Resulting reaction mixture was stirred for an hour.
  • Diboc-Lysdex-aziridine (compound of Formula IV where X and Y both are Boc; 25.0 g) was dissolved in isopropyl alcohol (150.0 mL) and resulting solution was stirred for 15 minutes to obtain clear solution. Pd/C (0.15 g) was added to the reaction mixture and was kept under hydrogen pressure for 3 hours at 40 psi. Completion of reaction was checked by TLC. Pd/C was filtered and washed with IPA (50.0 mL). The reaction mixture was then concentrated under reduced pressure below 80 °C.
  • Diboc-lisdexamphetamine (25.0 g) was dissolved in 1,4-dioxane (175.0 mL) and was kept under stirring for 15 min under inert atmosphere. Methanesulfonic acid (15.56 g) was slowly added to the reaction mixture with maintaining temperature below 25 °C. Reaction mixture was maintained under stirring for overnight. Completion of reaction was checked by TLC. Reaction mass was filtered and washed with dioxane (50.0 mL) to obtain white solid. End solid product was dried under reduced pressure overnight at 55- 60 °C.
  • the reaction mass was concentrated under reduced pressure below 80 °C to get solid residue.
  • the solid residue was treated with isopropylacetate (152 mL) and washed twice with acetic acid (8.0 g)/NaCl(60.0 g)/water mixture (240 mL).
  • the organic layer was further washed with aq. sodium bicarbonate solution (12.0 g in 240 mL water). Both layer were separated, the organic layer was then concentrated under reduced pressure below 65 °C and was dried under reduced pressure to get solid reaction product.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP16872573.7A 2015-12-11 2016-12-12 Verfahren zur herstellung von lisdexamphetamin Withdrawn EP3386944A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4670MU2015 2015-12-11
PCT/IN2016/050441 WO2017098533A2 (en) 2015-12-11 2016-12-12 Process for preparation of lisdexamphetamine

Publications (2)

Publication Number Publication Date
EP3386944A2 true EP3386944A2 (de) 2018-10-17
EP3386944A4 EP3386944A4 (de) 2019-08-28

Family

ID=59012856

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16872573.7A Withdrawn EP3386944A4 (de) 2015-12-11 2016-12-12 Verfahren zur herstellung von lisdexamphetamin

Country Status (4)

Country Link
EP (1) EP3386944A4 (de)
BR (1) BR112018011437A2 (de)
CA (1) CA3006537A1 (de)
WO (1) WO2017098533A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3199184A1 (en) 2020-11-18 2022-05-27 Felix Lustenberger Mdma prodrugs to assist psychotherapy
EP4215517B1 (de) 2021-07-22 2025-11-19 SCI Pharmtech Inc. Verbindung und verfahren zur herstellung von lisdexamfetamin
US11608312B1 (en) 2021-07-22 2023-03-21 Sci Pharmtech Inc. Compound and method for preparation of lisdexamfetamine
WO2026047284A1 (en) 2024-08-28 2026-03-05 Fermion Oy Method for the preparation of lisdexamfetamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008864B1 (ru) * 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
US8487134B2 (en) * 2008-10-09 2013-07-16 Archimica, Inc. Process for the synthesis of amphetamine derivatives
US8614346B2 (en) * 2009-06-19 2013-12-24 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
US8779191B2 (en) * 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
WO2013011526A1 (en) * 2011-07-20 2013-01-24 Ind-Swift Laboratories Limited Process for preparation of lisdexamphetamine and salts thereof
WO2015130660A1 (en) * 2014-02-25 2015-09-03 Chemapotheca, Llc Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds

Also Published As

Publication number Publication date
EP3386944A4 (de) 2019-08-28
CA3006537A1 (en) 2017-06-15
BR112018011437A2 (pt) 2018-11-27
WO2017098533A3 (en) 2017-08-10
WO2017098533A2 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
JP7100125B2 (ja) リボシクリブおよびその塩の改善された調製のためのプロセス
JP7139511B2 (ja) ペプチド化合物の製造方法、保護基形成用試薬、及び、縮合多環芳香族炭化水素化合物
CA3077888C (en) Indacaterol free base in solid form
EP3386944A2 (de) Verfahren zur herstellung von lisdexamphetamin
WO2016125191A2 (en) Processes for the preparation of vortioxetine hydrobromide
JP2016539931A (ja) テトラペプチド化合物及びその製造方法
WO2019026014A1 (en) METHODS FOR PREPARING LIFITEGRAST AND ITS INTERMEDIATES
WO2016079699A1 (en) Process for the preparation of (4r)-1-(tert-butoxycarbonyl)-4-hydroxy-l-proline
CN111051289A (zh) 被保护的l-肌肽衍生物、l-肌肽以及结晶性l-肌肽锌络合物的制造方法
NZ553973A (en) Process for preparing the L-monovaline ester derived from 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propane-diol
CN106146502A (zh) 艾代拉里斯的合成方法及制备中间体
WO2015019239A1 (en) Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
CA2960473A1 (en) Processes for the preparation of tadalafil and intermediates thereof
WO2021176473A1 (en) A process for the preparation of upadacitinib and its intermediates
US20100256370A1 (en) Process for the Preparation of Alfuzosin Hydrochloride
JP3944077B2 (ja) エリスロマイシン誘導体の製造方法
EP4628492A1 (de) Herstellungsverfahren für linker-wirkstoff-konjugat und zwischenprodukt davon
WO2015063709A1 (en) Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
WO2015110886A1 (en) A process for preparation of (2s, 5r)-7-oxo-n-[(3s)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide
JP2025001049A (ja) アルギニン誘導体
WO2014155264A1 (en) Process for the preparation of lacosamide using novel intermediates
KR101628946B1 (ko) 실로도신의 개선된 제조방법
CN110627768A (zh) 一种莫西沙星降解杂质j的制备方法
JP2024080578A (ja) ミラベグロン及びその製造中間体の製造方法
WO2004080946A1 (en) Process for the preparation of midodrine, pharmaceutically-acceptable salts thereof and intermediates

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180626

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190725

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 231/14 20060101ALI20190719BHEP

Ipc: C07D 203/18 20060101AFI20190719BHEP

Ipc: C07C 237/06 20060101ALI20190719BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200225